Powder: -20°C for 3 years | In solvent: -80°C for 1 year
D8-MMAE (D8-Monomethyl auristatin E) is an effective mitotic inhibitor and tubulin inhibitor, deuterated MMAE.
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
25 mg | 待询 | 10-14周 | ||
50 mg | 待询 | 10-14周 | ||
100 mg | 待询 | 10-14周 |
MMAE-d8 的其他形式现货产品:
产品描述 | D8-MMAE (D8-Monomethyl auristatin E) is an effective mitotic inhibitor and tubulin inhibitor, deuterated MMAE. |
体外活性 | Antibody-drug conjugates (ADC) contain targeted antibodies with effective small molecule payloads. The ADC is produced against different receptors on the anaplastic large cell lymphoma L-82 line, but delivers the same cytotoxic payload (monomethyl auristatin E, MMAE). ADC-mediated cytotoxicity is not related to target expression or drug: antibody ratio. LC-MS was used to measure the concentration of MMAE in the L-82 tumor parallel cohort by the same treatment protocol. Although there was no difference in tumor volume between the treatment groups 3 days after administration, intratumoral MMAE measurements showed two patterns. First, the MMAE concentration in the tumor increases in proportion to the ADC dose, which corresponds to stronger antitumor activity. Second, intra-tumor MMAE concentrations obtained after treatment with cOKT9-vcMMAE and cAC10-vcMMAE were similar at each dose, which is consistent with the observation that tumors responded similarly to these two ADCs. |
体内活性 | In tumor xenograft models, the MMAE concentration in the tumor is always correlated with the degree of tumor growth inhibition. IHC analysis showed that tumors that were not combined with control treatment consisted of CD30 + and CD30 cells, presumably because they did not kill CD30 + or CD30- Karpas 299 cells. Only CD30-cells were found in tumors treated with cAC10-vcMMAF, indicating that cAC10-vcMMAF eliminated most CD30 + cells. Interestingly, at the end of the study, two tumors recurring from the treatment of cAC10-vcMMAE were also found to be CD30-, indicating that in the remaining two tumors, a small portion of CD30-cells may have escaped bystanders Kill. |
别名 | D8-MMAE, D8-Monomethyl auristatin E |
分子量 | 726.03 |
分子式 | C39H59D8N5O7 |
CAS No. | 2070009-72-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 100 mg/mL (137.74 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.3774 mL | 6.8868 mL | 13.7735 mL | 34.4338 mL |
5 mM | 0.2755 mL | 1.3774 mL | 2.7547 mL | 6.8868 mL | |
10 mM | 0.1377 mL | 0.6887 mL | 1.3774 mL | 3.4434 mL | |
20 mM | 0.0689 mL | 0.3443 mL | 0.6887 mL | 1.7217 mL | |
50 mM | 0.0275 mL | 0.1377 mL | 0.2755 mL | 0.6887 mL | |
100 mM | 0.0138 mL | 0.0689 mL | 0.1377 mL | 0.3443 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
MMAE-d8 2070009-72-0 Others MMAE-d-8 MMAE d8 D8-MMAE MMAEd8 D8-Monomethyl auristatin E Inhibitor inhibitor inhibit